Biolase gets access to wider market in the US:
This article was originally published in Clinica
Executive Summary
In a move that expands the market for its products Biolase Technology has received US FDA approval to sell its LaserSmile dental laser as a treatment for periodontal disease. Previously cleared for just cosmetic and soft-tissue applications, the device can now be used to treat both early and advanced stages of periodontal disease, which the firm claims is a US first for a 810nm solid-state laser. More than 30% of adults over 50 years of age suffer from periodontal disease, said the San Clemente, California firm.
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.